Rotterdam, The Netherlands (February 13, 2020) Parx Materials N.V. (Euronext: MLPRX) announces that it has received a capital injection of EUR 1.0 million for expansion and scale-up. This investment allows Parx Materials (as of January 29 the new name of the company formerly named Parx Plastics) to expand its team and make the required investments for the scaling up of the production of Saniconcentrate.
The Belgium company Lausha N.V. is making the capital injection and is obtaining an equity stake of 12.5%.
With the recent developments, Parx is making exciting steps in the development and commercializing of its unique antimicrobial and antibiofilm technology. On December 20 the company was able to announce a signed cooperation agreement with PepsiCo in Purchase, New York and it is seeing excellent adoption of its technology in the supermarket channel in the UK and elsewhere.
About Parx Materials
Parx specializes in the development and manufacturing of materials with sustainable antimicrobial and antibiofilm properties. The company's technology does not use harmful or toxic chemicals, biocides, heavy metals or nanoparticles. It can be used with any type of plastic and for any type of application. It is fully biocompatible and it does not diffuse out of the material. Also, it prevents bacteria and microorganisms pilling up on the surface of a product with an efficacy of 99,9% and higher within 24 hours. For more information visit www.parxmaterials.com
Parx Materials NV contacts:
Parx Materials NV
Stationsplein 45, Unit A4.004
3013 AK Rotterdam
tel: +31 (0)10 34 000 95